Literature DB >> 29903862

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.

Emanuele Pontali1, Giovanni Sotgiu2, Simon Tiberi3,4, Marina Tadolini5, Dina Visca6, Lia D'Ambrosio7, Rosella Centis6, Antonio Spanevello6,8, Giovanni Battista Migliori6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29903862     DOI： 10.1183/13993003.00934-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  9 in total

1.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

2.  Treatment as prevention and other interventions to reduce transmission of multidrug-resistant tuberculosis.

Authors:  R R Nathavitharana; P Lederer; D B Tierney; E Nardell
Journal:  Int J Tuberc Lung Dis       Date:  2019-04-01       Impact factor: 2.373

Review 3.  Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.

Authors:  Johanna Kuhlin; Marieke G G Sturkenboom; Samiksha Ghimire; Ioana Margineanu; Simone H J van den Elsen; Noviana Simbar; Onno W Akkerman; Erwin M Jongedijk; Remco A Koster; Judith Bruchfeld; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Clin Mass Spectrom       Date:  2018-10-19

4.  Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  Hossein Hatami; Giovanni Sotgiu; Narjess Bostanghadiri; Sahel Shafiee Dolat Abadi; Bita Mesgarpour; Hossein Goudarzi; Giovanni Battista Migliori; Mohammad Javad Nasiri
Journal:  J Bras Pneumol       Date:  2022-05-30       Impact factor: 2.800

5.  A new era for treatment of drug-resistant tuberculosis.

Authors:  Neel R Gandhi; James C M Brust; N Sarita Shah
Journal:  Eur Respir J       Date:  2018-10-04       Impact factor: 16.671

6.  QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.

Authors:  Kelly E Dooley; Susan L Rosenkranz; Francesca Conradie; Laura Moran; Richard Hafner; Florian von Groote-Bidlingmaier; Javier R Lama; Justin Shenje; Jorge De Los Rios; Kyla Comins; Joel Morganroth; Andreas H Diacon; Yoninah S Cramer; Kathleen Donahue; Gary Maartens
Journal:  Lancet Infect Dis       Date:  2021-02-12       Impact factor: 71.421

7.  TB management in the European Union/European Economic Area: a multi-centre survey.

Authors:  G Sotgiu; S Rosales-Klintz; R Centis; L D'Ambrosio; R Verduin; A M Correia; A Cirule; R Duarte; B Gadzheva; G Gualano; H Kunst; F Palmieri; V Riekstina; D Stefanova; S Tiberi; M J van der Werf; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2021-02-01       Impact factor: 2.373

Review 8.  Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach.

Authors:  Theresa Ryckman; Katherine Robsky; Lucia Cilloni; Stella Zawedde-Muyanja; Ramya Ananthakrishnan; Emily A Kendall; Sourya Shrestha; Stavia Turyahabwe; Achilles Katamba; David W Dowdy
Journal:  Lancet Infect Dis       Date:  2022-08-10       Impact factor: 71.421

9.  Characteristics and Treatment Outcomes of Patients with Tuberculosis Receiving Adjunctive Surgery in Uzbekistan.

Authors:  Anvar Riskiyev; Ana Ciobanu; Arax Hovhannesyan; Kristina Akopyan; Jamshid Gadoev; Nargiza Parpieva
Journal:  Int J Environ Res Public Health       Date:  2021-06-17       Impact factor: 3.390
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.